US FDA announces new priority vouchers for accelerated review times
.png)
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening the FDA’s review time to 1-2 months following final drug application submissions.
Through the program, a new process for the FDA will convene experts from FDA offices for team-based review as opposed to the standard process of sending a drug’s application to different FDA offices and departments. “Using a common-sense approach, the national priority review program will allow companies to submit the lion’s share of the drug application before a clinical trial is complete so that we can reduce inefficiencies,” stated US FDA Commissioner Marty Makary in a press announcement by the US FDA. “The ultimate goal is to bring more cures and meaningful treatments to the American public.”
A limited number of vouchers will be offered in the pilot year of the program, aimed at companies who align with US national priorities. The program may also offer these companies accelerated approval if the product meets applicable legal requirements for such steps. The CNPV program will also enhance communication with the drug sponsor throughout the review process. The FDA Commissioner’s office released specific criteria for companies looking to nab one of the limited vouchers, including addressing a health crisis in the US, delivering more innovative cures for the American people, addressing unmet public health needs, and increasing domestic drug manufacturing as a national security issue. Companies must qualify by submitting the chemistry, manufacturing, and controls portion of an application as well as draft labelling at least 60 days before a final application, and must be available for ongoing communication with the FDA. Potential companies can utilise the vouchers towards a specific investigational new drug or hold an undesignated voucher, which will allow the drug sponsor to use it for a new drug consistent with the CNPV’s objectives.
In the same statement by the FDA, Principal Deputy Commissioner Sara Brenner commented “This approach capitalises on frequent communication with sponsors, which can be a powerful tool in reducing wasted time. We are confident this more efficient process can be achieved without cutting any corners on safety or scientific evaluation.”
Source:
FDA to Issue New Commissioner’s National Priority Vouchers to Companies Supporting U.S. National Interests [Accessed June 18, 2025] https://www.fda.gov/news-events/press-announcements/fda-issue-new-commissioners-national-priority-vouchers-companies-supporting-us-national-interests
Related News
-
News AstraZeneca invests in AI-led research agreement with China's CSPC, up to US$5.3 billion
Anglo-Swedish pharmaceutical giant AstraZeneca announced they have signed a deal with China’s CSPC Pharmaceutical Group worth up to US$5.3 billion to drive AI-led research development of therapies for chronic conditions.
-
News CPHI Americas 2025 - From the Floor
Our From the Floor live blog is back in Philadelphia for this year’s CPHI, this time under the new name CPHI Americas to embrace and represent the whole of the pharmaceutical supply chain from north to south.
-
News Women in Pharma: Unlocking patient inclusion at CPHI Americas
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can towards making the healthcare industry and workplace more equitable and inclusive.&nbs... -
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Executive order to elevate US pharma manufacturing signed by Trump
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.